Treatment landscape of triple-negative breast cancer — expanded options, evolving needs von Bianchini, Giampaolo, De Angelis, Carmine, Licata, Luca, Gianni, Luca

Volltext

Towards personalized treatment for early stage HER2-positive breast cancer von Goutsouliak, Kristina, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, De Angelis, Carmine, Osborne, C. Kent, Rimawi, Mothaffar F., Schiff, Rachel

Volltext

FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer von Fu, Xiaoyong, Jeselsohn, Rinath, Pereira, Resel, Hollingsworth, Emporia F., Creighton, Chad J., Li, Fugen, Shea, Martin, Nardone, Agostina, De Angelis, Carmine, Heiser, Laura M., Anur, Pavana, Wang, Nicholas, Grasso, Catherine S., Spellman, Paul T., Griffith, Obi L., Tsimelzon, Anna, Gutierrez, Carolina, Huang, Shixia, Edwards, Dean P., Trivedi, Meghana V., Rimawi, Mothaffar F., Lopez-Terrada, Dolores, Hilsenbeck, Susan G., Gray, Joe W., Brown, Myles, Osborne, C. Kent, Schiff, Rachel

Volltext

NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer von Bhat, Raksha, Thangavel, Hariprasad, Abdulkareem, Noor Mazin, Vasaikar, Suhas, De Angelis, Carmine, Bae, Leon, Cataldo, Maria Letizia, Nanda, Sarmistha, Fu, Xiaoyong, Zhang, Bing, Schiff, Rachel, Trivedi, Meghana V.

Volltext

Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic von Fu, Xiaoyong, De Angelis, Carmine, Schiff, Rachel

Volltext

Ribociclib in newly diagnosed hepatitis B infection: A case report von Di Costanzo, Fabrizio, Carrano, Simone, Iengo, Gennaro, Cefaliello, Amedeo, Cossiga, Valentina, Morisco, Filomena, Giuliano, Mario, De Angelis, Carmine, Arpino, Grazia

Volltext

What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research A... von Moretti, Anna, Ghidini, Michele, De Angelis, Carmine, Lambertini, Matteo, Cremolini, Chiara, Imbimbo, Martina, Berardi, Rossana, Di Maio, Massimo, Cascinu, Stefano, La Verde, Nicla

Volltext

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer von Jeselsohn, Rinath, De Angelis, Carmine, Brown, Myles, Schiff, Rachel

Volltext

Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance von Bi, Mingjun, Zhang, Zhao, Jiang, Yi-Zhou, Xue, Pengya, Wang, Hu, Lai, Zhao, Fu, Xiaoyong, De Angelis, Carmine, Gong, Yue, Gao, Zhen, Ruan, Jianhua, Jin, Victor X., Marangoni, Elisabetta, Montaudon, Elodie, Glass, Christopher K., Li, Wei, Huang, Tim Hui-Ming, Shao, Zhi-Ming, Schiff, Rachel, Chen, Lizhen, Liu, Zhijie

Volltext

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance von Jeselsohn, Rinath, Cornwell, MacIntosh, Pun, Matthew, Buchwalter, Gilles, Nguyen, Mai, Bango, Clyde, Huang, Ying, Kuang, Yanan, Paweletz, Cloud, Fu, Xiaoyong, Nardone, Agostina, De Angelis, Carmine, Detre, Simone, Dodson, Andrew, Mohammed, Hisham, Carroll, Jason S., Bowden, Michaela, Rao, Prakash, Long, Henry W., Li, Fugen, Dowsett, Mitchell, Schiff, Rachel, Brown, Myles

Volltext

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer von Fu, Xiaoyong, Pereira, Resel, De Angelis, Carmine, Veeraraghavan, Jamunarani, Nanda, Sarmistha, Qin, Lanfang, Cataldo, Maria L., Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Gutierrez, Carolina, Chamness, Gary C., Feng, Qin, O’Malley, Bert W., Selenica, Pier, Weigelt, Britta, Reis-Filho, Jorge S., Cohen, Ofir, Wagle, Nikhil, Nardone, Agostina, Jeselsohn, Rinath, Brown, Myles, Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

Volltext

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models von Veeraraghavan, Jamunarani, Gutierrez, Carolina, Sethunath, Vidyalakshmi, Mehravaran, Sepideh, Giuliano, Mario, Shea, Martin J., Mitchell, Tamika, Wang, Tao, Nanda, Sarmistha, Pereira, Resel, Davis, Robert, Goutsouliak, Kristina, Qin, Lanfang, De Angelis, Carmine, Diala, Irmina, Lalani, Alshad S., Nagi, Chandandeep, Hilsenbeck, Susan G., Rimawi, Mothaffar F., Osborne, C. Kent, Schiff, Rachel

Volltext

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis von Wu, Yanming, Zhang, Zhao, Cenciarini, Mauro E, Proietti, Cecilia J, Amasino, Matias, Hong, Tao, Yang, Mei, Liao, Yiji, Chiang, Huai-Chin, Kaklamani, Virginia G, Jeselsohn, Rinath, Vadlamudi, Ratna K, Huang, Tim Hui-Ming, Li, Rong, De Angelis, Carmine, Fu, Xiaoyong, Elizalde, Patricia V, Schiff, Rachel, Brown, Myles, Xu, Kexin

Volltext

The changing role of ER in endocrine resistance von Nardone, Agostina, De Angelis, Carmine, Trivedi, Meghana V, Osborne, C. Kent, Schiff, Rachel

Volltext

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2 + Breast Cancer von Xu, Xiaowei, De Angelis, Carmine, Burke, Kathleen A, Nardone, Agostina, Hu, Huizhong, Qin, Lanfang, Veeraraghavan, Jamunarani, Sethunath, Vidyalakshmi, Heiser, Laura M, Wang, Nicholas, Ng, Charlotte K Y, Chen, Edward S, Renwick, Alexander, Wang, Tao, Nanda, Sarmistha, Shea, Martin, Mitchell, Tamika, Rajendran, Mahitha, Waters, Ian, Zabransky, Daniel J, Scott, Kenneth L, Gutierrez, Carolina, Nagi, Chandandeep, Geyer, Felipe C, Chamness, Gary C, Park, Ben H, Shaw, Chad A, Hilsenbeck, Susan G, Rimawi, Mothaffar F, Gray, Joe W, Weigelt, Britta, Reis-Filho, Jorge S, Osborne, C Kent, Schiff, Rachel

Volltext

A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer von Servetto, Alberto, Napolitano, Fabiana, De Angelis, Carmine, De Placido, Pietro, Giuliano, Mario, Arpino, Grazia, De Placido, Sabino, Bianco, Roberto, Formisano, Luigi

Volltext

Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer von Sethunath, Vidyalakshmi, Hu, Huizhong, De Angelis, Carmine, Veeraraghavan, Jamunarani, Qin, Lanfang, Wang, Nicholas, Simon, Lukas M, Wang, Tao, Fu, Xiaoyong, Nardone, Agostina, Pereira, Resel, Nanda, Sarmistha, Griffith, Obi L, Tsimelzon, Anna, Shaw, Chad, Chamness, Gary C, Reis-Filho, Jorge S, Weigelt, Britta, Heiser, Laura M, Hilsenbeck, Susan G, Huang, Shixia, Rimawi, Mothaffar F, Gray, Joe W, Osborne, C Kent, Schiff, Rachel

Volltext

A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer von Abdulkareem, Noor Mazin, Bhat, Raksha, Qin, Lanfang, Vasaikar, Suhas, Gopinathan, Ambily, Mitchell, Tamika, Shea, Martin J., Nanda, Sarmistha, Thangavel, Hariprasad, Zhang, Bing, De Angelis, Carmine, Schiff, Rachel, Trivedi, Meghana V.

Volltext

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study von Buono, Giuseppe, Crispo, Anna, Giuliano, Mario, De Angelis, Carmine, Schettini, Francesco, Forestieri, Valeria, Lauria, Rossella, De Laurentiis, Michelino, De Placido, Pietro, Rea, Carmen Giusy, Pacilio, Carmen, Esposito, Emanuela, Grimaldi, Maria, Nocerino, Flavia, Porciello, Giuseppe, Giudice, Aldo, Amore, Alfonso, Minopoli, Anita, Botti, Gerardo, De Placido, Sabino, Trivedi, Meghana V., Arpino, Grazia

Volltext

Editorial: Molecular predictive pathology in gynecologic malignancies von Malapelle, Umberto, Uccella, Stefano, Cecere, Sabrina Chiara, De Angelis, Carmine, Giampaolino, Pierluigi

Volltext